Robert Schott

Company: Rivus Pharmaceuticals Inc.

Job title: Chief Medical Officer

Bio:

Robert Schott, M.D., adds deep experience in clinical development to the Rivus executive team in his role as Chief Medical Officer, including expertise in advancing mRNA therapeutics and gene and cell therapies across diverse indications. He joined the company from Nutcracker Therapeutics, where he served as Chief Medical Officer, and before that, was a Senior Vice President and Head of Development at Sangamo Therapeutics. Dr. Schott was also previously at Eli Lilly for nearly seven years, most recently serving as Chief Medical Officer for Chorus, the autonomous early-phase drug development group inside of Lilly. Dr. Schott earned a B.S. in Biomedicine from the University of Michigan, an M.D. from the University of Michigan Medical School and an M.P.H. in epidemiology from the University of Michigan School of Public Health. He completed an internal medicine residency at the University of Michigan Hospitals and a fellowship in cardiology at Massachusetts General Hospital.

Seminars:

Developing Controlled Metabolic Accelerators (CMAs) as a New Class of Investigational Medicines to Combat Obesity & Chronic Metabolic Diseases 11:00 am

Developing Controlled Metabolic Accelerators (CMAs) has the advantage of increasing metabolic rate without elevating heart rate, providing the benefit of a more tolerable and sustainable treatment for patients Targeting metabolic pathways directly allows for the preferential use of fat for fuel, resulting in the benefit of significant and selective fat reduction This novel mechanism of…Read more

day: Pre-Conference Day